ADMA - ADMA Biologics Inc logo

ADMA Biologics Inc

ADMA

ADMA Biologics develops and manufactures plasma-derived biologics for treating immune deficiencies and infectious diseases. Its product portfolio includes intravenous immune globulin therapies and a human polyclonal antibody for Hepatitis B, primarily targeting U.S. patients.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$1,385today

Score Overview

1 Year
Score
Net Growth14.99%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth0.41%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.5
Net Growth335.82%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth6x
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth10x
Net Trend60%
Net Income Consistency
Rev Growth48x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth12x
Net Trend46%
Net Income Consistency
Rev Growth166x
Rev Trend92%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where ADMA Biologics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. ADMA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 10.03โ€”
1 Year2025-09-30
$ 14.66-31.58%
5 Years2021-09-30
$ 1.138x
10 Years2016-09-30
$ 7.2438.54%
All Time2013-10-17
$ 8.5517.31%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 512M$ 168M$ 136M
2025$ 510M$ 146M$ 87M
2024$ 426M$ 197M$ 103M
2023$ 258M-$ 28M$ 51M
2022$ 154M-$ 65M$ 86M
2021$ 80M-$ 71M$ 51M
2020$ 42M-$ 75M$ 55M
2019$ 29M-$ 48M$ 26M
2018$ 16M-$ 65M$ 22M
2017$ 22M-$ 43M$ 43M
2016$ 10M-$ 19M$ 15M
2015$ 7M-$ 17M$ 16M
2014$ 5M-$ 16M$ 21M
IPO2013$ 3M-$ 15M$ 29M
ADMA - ADMA Biologics Inc logo

ADMA Biologics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 42M to $ 510M and net income went from -$ 75M to $ 146M. Revenue increased in every one of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 7M to $ 510M and net income went from -$ 17M to $ 146M. Revenue increased in 9 of those 10 years; net income in 6.

ADMA Biologics Inc currently holds a 5-year HDB Score of 8.5 out of 10. How the HDB Score is calculated.

Membership

Explore ADMA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies